BDX
HealthcareBecton, Dickinson and Company · Medical - Instruments & Supplies · $53B
What is Becton, Dickinson and Company?
Becton, Dickinson and Company is a global medical technology company that manufactures and sells medical supplies, devices, laboratory equipment, and diagnostic products to healthcare institutions and life science researchers worldwide.
The company earns revenue through two main segments: BD Medical, which covers infusion therapy, drug delivery, and diabetes care products, and BD Life Sciences, which provides specimen collection, diagnostic testing, and cell analysis solutions. Customers range from hospitals and clinical labs to pharmaceutical manufacturers.
Becton Dickinson has operated from its headquarters in Franklin Lakes, US, and traces its corporate roots to 1973 in its current form.
- Peripheral IV catheters and vascular access devices
- Automated medication dispensing and infusion systems
- Diagnostic and microbiology laboratory instruments
- Prefillable drug delivery systems
Is BDX a Good Stock to Buy?
UQS Score rates BDX as Below Average overall.
Among the five pillars, Valuation stands out as Attractive, suggesting the market may not be pricing in a premium for BDX relative to its fundamentals. The Moat pillar registers as Neutral, reflecting the company's established market presence in medical supplies.
Quality, Growth, and Risk all score as Weak, pointing to meaningful headwinds across profitability, expansion trajectory, and balance sheet or operational risk factors.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does BDX pay dividends?
Yes — Becton, Dickinson and Company pays a dividend.
BDX pays a regular dividend, consistent with its position as a large-cap healthcare company with a long operating history. The dividend reflects management's commitment to returning capital to shareholders, though investors should weigh this alongside the company's current Weak Quality and Growth pillar ratings.
When does BDX report earnings?
Becton Dickinson reports earnings on a quarterly cadence, typical for US-listed large-cap equities.
Recent results have reflected the pressures visible in BDX's Weak Growth and Quality pillar ratings, with the business navigating a challenging environment for medical device demand and cost management. Investors should track segment-level trends across BD Medical and BD Life Sciences.
For the most recent quarter's results, visit Becton Dickinson's investor relations page directly.
BDX Price History
+19.2% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Becton, Dickinson and Company?
Based on Becton, Dickinson and Company's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Becton Dickinson do?
Becton Dickinson develops and sells medical supplies, devices, laboratory equipment, and diagnostic products. Its two segments — BD Medical and BD Life Sciences — serve hospitals, clinical laboratories, pharmaceutical companies, and life science researchers around the world.
Does BDX pay dividends?
Yes, BDX pays a regular dividend. It has a history of returning capital to shareholders through dividends, which is common among established large-cap healthcare companies. Check the company's investor relations page for the current dividend rate and payment schedule.
When does BDX report earnings?
Becton Dickinson reports on a quarterly cadence, as is standard for US-listed companies. For the exact dates of upcoming earnings releases, refer to the investor relations section of the Becton Dickinson website.
Is BDX a good stock to buy?
UQS Score rates BDX as Below Average. While Valuation appears Attractive, the Quality, Growth, and Risk pillars all register as Weak. That combination warrants careful review before investing. The full pillar breakdown is available to UQS Pro members.
Is BDX overvalued?
Based on the UQS Valuation pillar, BDX is rated Attractive, meaning the current price may offer relative value compared to the company's fundamentals. However, an attractive valuation alone does not offset weaknesses in other pillars such as Quality and Growth.
What is BDX's market cap bracket?
BDX is classified as a large-cap stock, reflecting its scale as one of the more established players in the global medical technology sector.
Is BDX a long-term quality investment?
As a long-term quality indicator, BDX's current UQS profile is Below Average. The Weak ratings across Quality, Growth, and Risk suggest the business faces real challenges that long-term investors should monitor closely. Pro members can access the complete analysis.
What sector does BDX belong to?
BDX operates in the Healthcare sector, specifically within medical technology. It competes in areas such as vascular access, drug delivery, diagnostic instruments, and life science research tools.
Unlock Full BDX Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings for BDX
- ✓Access full financial metrics and trend data
- ✓Compare BDX against sector peers on every pillar
- ✓Get the complete analyst-style quality breakdown in one place
Pro Analysis
BDX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 42.1 | 36.1 | 46.0 | 31.9 | 25.7 | 75.5 | -0.2 |
| May 22, 2026 | 42.3 | 36.1 | 46.0 | 31.9 | 25.7 | 76.9 | -0.1 |
| May 19, 2026 | 42.4 | 36.1 | 46.0 | 31.9 | 25.7 | 77.3 | +0.1 |
| May 17, 2026 | 42.3 | 36.1 | 46.0 | 31.9 | 25.7 | 77.0 | -0.2 |
| May 16, 2026 | 42.5 | 36.1 | 46.0 | 31.9 | 25.7 | 78.2 | -0.2 |
| May 14, 2026 | 42.7 | 36.1 | 46.0 | 31.9 | 25.7 | 79.6 | 0.0 |
| May 13, 2026 | 42.7 | 35.7 | 46.0 | 31.9 | 25.7 | 80.4 | -0.2 |
| May 12, 2026 | 42.9 | 35.7 | 46.0 | 31.9 | 25.7 | 81.5 | +0.3 |
| May 11, 2026 | 42.6 | 35.7 | 46.0 | 31.9 | 25.7 | 79.9 | +0.4 |
| May 10, 2026 | 42.2 | 33.8 | 46.0 | 31.9 | 25.7 | 80.0 | 0.0 |
BDX — Pillar Breakdown
Quality
— 36.1/100 (25%)Becton, Dickinson and Company has average quality metrics, with room for improvement in margins or capital efficiency.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 31.9/100 (20%)Becton, Dickinson and Company faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 25.7/100 (15%)Becton, Dickinson and Company presents elevated risk with concerns around leverage or financial stability.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 77.4/100 (15%)Becton, Dickinson and Company appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 46/100 (25%)Becton, Dickinson and Company possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for BDX.
Score Composition
Financial Data
More Stock Analysis
How is the BDX UQS Score Calculated?
The UQS (Unified Quality Score) for Becton, Dickinson and Company is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Becton, Dickinson and Company's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Becton, Dickinson and Company is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.